{"": [122, 836, 0], "INTRODUCTION": [837, 1814, 0], "SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)": [1815, 2471, 0], "SPIKE: A MAJOR TARGET ANTIGEN FOR COVID-19 VACCINES": [2472, 8424, 0], "mRNA vaccines": [9925, 12869, 0], "Adenoviral-vectored vaccines": [12870, 16536, 0], "Inactivated virus vaccines": [16537, 18592, 0], "Recombinant protein subunit vaccines": [18593, 21092, 0], "DNA vaccines": [21093, 22821, 0], "COVID-19 VACCINES IN LATER STAGES OF DEVELOPMENT": [8425, 22821, 1], "Immune correlates of protection (ICP)": [22864, 26025, 0], "VAERD and ADE of disease": [26026, 27980, 0], "Pre-existing memory response cross-reactive to SARS-CoV-2": [27981, 29896, 0], "EFFICACY AND SAFETY OF COVID-19 VACCINES": [22822, 29896, 1], "CONCLUDING REMARKS": [29897, 31059, 0]}